Oxaliplatin and bevacizumab disappoint for rectal cancer
The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results. (Source: MedWire News - Gastroenterology)
Source: MedWire News - Gastroenterology - January 10, 2013 Category: Gastroenterology Source Type: news
Oxaliplatin and bevacizumab disappoint for rectal cancer
The addition of bevacizumab and oxaliplatin to standard neoadjuvant chemoradiotherapy does not enhance clinical response rates in rectal cancer, show phase II study results. (Source: MedWire News - Oncology)
Source: MedWire News - Oncology - January 10, 2013 Category: Cancer & Oncology Source Type: news
New NCCN Treatment Recommendations for Colon and Rectal Cancers
ROCKLEDGE, PA, February 4, 2003 - The National Comprehensive Cancer Network (NCCN) announces the publication of the first of the 2003 NCCN Clinical Practice Guidelines in Oncology, the Colon and Rectal Cancer Treatment Guidelines, in the January edition of JNCCN, the official journal of the NCCN. These updated guidelines contain new treatment recommendations regarding the use of the recently approved agent, oxaliplatin, and of radiation therapy in Stage II, III, and IV disease.
“The inclusi... (Source: National Comprehensive Cancer Network)
Source: National Comprehensive Cancer Network - February 4, 2003 Category: Cancer & Oncology Source Type: news
